• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–44. https://doi.org/10.1016/j.jaad.2016.12.005. Provides a broad overview of the use of JAK inhibitors in various dermatologic conditions.

• Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part I. A comprehensive review. J Am Acad Dermatol. 2022;86(2):406–13. https://doi.org/10.1016/j.jaad.2021.07.002. Part 1 of a two-part review of JAK inhibitors in dermatology focusing on atopic dermatitis and psoriasis. Part 1 also covers select smaller studies addressing other dermatologic conditions such as hidradenitis suppurativa and graft vs host disease.

Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https://doi.org/10.1038/s41392-021-00791-1.

Article  PubMed  PubMed Central  Google Scholar 

Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5). https://doi.org/10.3390/pharmaceutics14051001.

Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729–49. https://doi.org/10.1007/s13555-023-00892-5.

Article  PubMed  Google Scholar 

Aihie O, Dyer JA. JAK Inhibitors: a new weapon in the skin care providers’ arsenal. Mo Med. 2023;120(1):45–8.

PubMed  PubMed Central  Google Scholar 

• Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part II. A comprehensive review. J Am Acad Dermatol. 2022;86(2):414–22. https://doi.org/10.1016/j.jaad.2021.06.873. Part 2 of a two-part review of JAK inhibitors in dermatology focusing on conditions such as alopecia areata, vitiligo, sarcoidosis, and systemic lupus erythematosus.

King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518–29. https://doi.org/10.1016/S0140-6736(23)00222-2.

Article  CAS  PubMed  Google Scholar 

Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11. https://doi.org/10.1016/j.jaci.2018.10.032.

Article  PubMed  Google Scholar 

Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–40. https://doi.org/10.1016/j.jaci.2021.08.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eichner A, Wohlrab J. Pharmacology of inhibitors of Janus kinases - part 1: pharmacokinetics. J Dtsch Dermatol Ges. 2022;20(11):1485–99. https://doi.org/10.1111/ddg.14921.

Article  PubMed  Google Scholar 

Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. https://doi.org/10.3389/fimmu.2019.02847.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66. https://doi.org/10.1016/S0140-6736(20)30732-7. Results from a randomised phase 3 trial supporting the safety profile and efficacy of abrocitinib in patients ages 12 and over with moderate-to-severe atopic dermatitis.

•• Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–68. https://doi.org/10.1016/S0140-6736(21)00588-2. Results from two different phase 3 trials suggesting upadacitinib monotherapy may be a safe, effective option in teenagers and adults with atopic dermatitis.

King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two Phase 3 Trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–99. https://doi.org/10.1056/NEJMoa2110343.

Article  CAS  PubMed  Google Scholar 

• Chang PH, Huang SF, Chang PS, Yu Y. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol. 2021;48(11):1631–9. https://doi.org/10.1111/1346-8138.16116. Reviews the evidence of the safety and adverse effects of JAK inhibitors used in the treatment of atopic dermatitis.

•• Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–72. https://doi.org/10.1016/j.jaad.2021.04.085. Results from 2 phase 3 trials supporting the safety and efficacy of the topical JAK inhibitor ruxolitinib cream in treating atopic dermatitis.

•• Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaci D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. https://doi.org/10.1016/j.jaad.2022.07.002. Results from a phase 3 trial supporting the efficacy and safety profile of deucravacitinib compared with placebo and apremilast in plaque psoriasis.

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–9. https://doi.org/10.1001/jamadermatol.2019.2855.

Article  PubMed  PubMed Central  Google Scholar 

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019;181(4):733–42. https://doi.org/10.1111/bjd.17932.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612–7. https://doi.org/10.1002/art.39761.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12(1):7140. https://doi.org/10.1038/s41598-022-10777-w. Restrospective study of the WHO pharmacovigilance database assessing safety data and adverse effects of the first three approved JAK inhibitors: ruxolitinib, tofacitinib and baricitinib.

Greif CS, Srivastava D, Nijhawan RI. Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol. 2021;22(2):11. https://doi.org/10.1007/s11864-020-00815-y.

Article  PubMed  Google Scholar 

Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152(2):164–72. https://doi.org/10.1001/jamadermatol.2015.3029.

Article  PubMed  PubMed Central  Google Scholar 

Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837–52. https://doi.org/10.3899/jrheum.130683.

Article  CAS  PubMed  Google Scholar 

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841–50. https://doi.org/10.1016/j.jaad.2016.01.013.

Article  CAS  PubMed  Google Scholar 

Jordan Bruno X, Koh I, Lutsey PL, Walker RF, Roetker NS, Wilkinson K, et al. Venous thrombosis risk during and after medical and surgical hospitalizations: the medical inpatient thrombosis and hemostasis (MITH) study. J Thromb Haemost. 2022;20(7):1645–52. https://doi.org/10.1111/jth.15729.

Article  PubMed  PubMed Central  Google Scholar 

Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39(8):755–62. https://doi.org/10.1007/s40264-016-0431-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i34–42. https://doi.org/10.1093/rheumatology/key287.

Article  CAS  PubMed  Google Scholar 

Wieringa JW, van der Woude CJ. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2020;44–45:101665. https://doi.org/10.1016/j.bpg.2019.101665.

Article  PubMed  Google Scholar 

• Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71–87. https://doi.org/10.1136/annrheumdis-2020-218398. A consensus study that assesses the efficacy and safety of JAK inhibitors and provides points to consider/management guidelines.

Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel). 2019;6(12). https://doi.org/10.3390/children6120133.

Gochnauer H, Valdes-Rodriguez R, Cardwell L, Anolik RB. The psychosocial impact of atopic dermatitis. Adv Exp Med Biol. 2017;1027:57–69. https://doi.org/10.1007/978-3-319-64804-0_6.

Article  PubMed  Google Scholar 

Haque A, Ahmed F, Amanullah A. Atopic dermatitis therapeutic algorithm of JAK-inhibitors and IL-4/IL-13 antagonists utilizing patient profiles and drug efficacy. J Clin Aesthet Dermatol. 2023;16(2):11–3.

PubMed  PubMed Central  Google Scholar 

Kwa L, Silverberg JI. Emergency department visits for atopic dermatitis are common and costly in the United States. Journal of the American Academy of Dermatology. 2018;79(3):Ab128–Ab.

Edigin E, Kichloo A, El-Amir Z, Wani F, Eseaton PO, Shaka H. National trends in hospitalizations of atopic dermatitis adult patients: a 21-year longitudinal United States population-based study. J Am Acad Dermatol. 2022;87(1):153–7. https://doi.org/10.1016/j.jaad.2021.06.882.

Article  PubMed  Google Scholar 

Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. https://doi.org/10.4161/jkst.24137.

Article  PubMed  PubMed Central  Google Scholar 

Stander S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE trial. Am J Clin Dermatol. 2023;24(1):97–107. https://doi.org/10.1007/s40257-022-00738-4.

Article  PubMed  Google Scholar 

Silverberg JI, Hong HC, Thyssen JP, Calimlim BM, Joshi A, Teixeira HD, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2022;12(5):1181–96. https://doi.org/10.1007/s13555-022-00721-1.

Article  PubMed  Google Scholar 

Fiuza-Luces C, Simpson RJ, Ramirez M, Lucia A, Berger NA. Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant. 2016;51(1):13–26. https://doi.org/10.1038/bmt.2015.195.

Article  CAS  PubMed  Google Scholar 

Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–52. https://doi.org/10.1038/nri2000.

Article  CAS  PubMed